September 08, 2016
DURHAM, N.C.–(BUSINESS WIRE)–Recent research has shed light on the predictability of fractures that fail to heal, known as nonunions. All nonunions are a function of severity, location and disease comorbidity and while risk factor interaction is complex, a new study reports that it may become possible to predict nonunion based on the patient-specific presentation of risk factors. The findings are published in the September 7, 2016 issue of JAMA Surgery available at http://archsurg.jamanetwork.com/article.aspx?articleid=2547685.
The study found that in 2011, among 309,330 fractures in 18 bones, the overall nonunion rate was 4.93%. However, higher nonunion risk was associated with severe fractures, high body mass index, smoking and alcoholism. While females had more fractures, males were more prone to nonunion. In addition, the risk of nonunion increased for patients who used certain medications including antibiotics, anticoagulants, and opioids, as well as for patients who had diseases such as obesity, osteoarthritis and osteoporosis.
“We hypothesized that the interplay between a patient’s physiological risk factors and fracture characteristics increased the risk of fracture nonunion,” said Dr. R. Grant Steen, Manager of Medical Affairs, Bioventus. “We now believe clinicians can use this information to describe the epidemiology of fracture nonunion in adult patients.”
The study was funded by Bioventus and used fracture patients from a health plan database. Patients with fracture were identified and continuous enrollment in the database was required for 12 months after fracture, to allow sufficient time to capture a nonunion diagnosis.
Authors of this study include Robert Zura, MD, LSU Health Science Center, New Orleans, Ze Xiong, MS, Dept. of Statistics, North Carolina State University, Thomas Einhorn, MD, NYU Langone Medical Center, J. Tracy Watson, MD Saint Louis University School of Medicine, Robert F. Ostrum, MD University of North Carolina, Michael J. Payson, MD, Wright State University, Gregory J. Della Rocca, MD, PhD, University of Missouri, Samir Mehta, MD, Hospital of the University of Pennsylvania, Todd McKinley, MD, Indiana University, Zhe Wang, MS, Dept. of Statistics, North Carolina State University and R. Grant Steen, PhD, Manager of Medical Affairs, Bioventus.
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Thomas Hill, 919-474-6715